Abstract
BackgroundSB2 is developed as a biosimilar of the infliximab reference product (INF). The clinical results of this Phase III study have been reported1,2.ObjectivesTo compare efficacy results (ACR responses, ACR-N, DAS28,...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
